ABSTRACT BACKGROUND: The role of the mechanistic target of rapamycin (mTOR) signaling in the antidepressant effects of ketamine is controversial. In addition to mTOR, extracellular signal-regulated kinase (ERK) is a key signaling molecule in prominent pathways that regulate protein synthesis. (R)-Ketamine has a greater potency and longer-lasting antidepressant effects than (S)-ketamine. Here we investigated whether mTOR signaling and ERK signaling play a role in the antidepressant effects of two enantiomers. METHODS: The effects of mTOR inhibitors (rapamycin and AZD8055) and an ERK inhibitor (SL327) on the antidepressant effects of ketamine enantiomers in the chronic social defeat stress (CSDS) model (n = 7 or 8) and on those of ketamine enantiomers in these signaling pathways in mouse brain regions were examined. RESULTS: The intracerebroventricular infusion of rapamycin or AZD8055 blocked the antidepressant effects of (S)-ketamine, but not (R)-ketamine, in the CSDS model. Furthermore, (S)-ketamine, but not (R)-ketamine, significantly attenuated the decreased phosphorylation of mTOR and its downstream effector, ribosomal protein S6 kinase, in the prefrontal cortex of susceptible mice after CSDS. Pretreatment with SL327 blocked the antidepressant effects of (R)-ketamine but not (S)-ketamine. Moreover, (R)-ketamine, but not (S)-ketamine, significantly attenuated the decreased phosphorylation of ERK and its upstream effector, mitogen-activated protein kinase/ERK kinase, in the prefrontal cortex and hippocampal dentate gyrus of susceptible mice after CSDS. CONCLUSIONS: This study suggests that mTOR plays a role in the antidepressant effects of (S)-ketamine, but not (R)-ketamine, and that ERK plays a role in (R)-ketamine's antidepressant effects. Thus, it is unlikely that the activation of mTOR signaling is necessary for antidepressant actions of (R)-ketamine.
Ketamine, an N-methyl-D-aspartate receptor antagonist, is the most prominent antidepressant for treatment-resistant depression (1-7). Berman et al. (7) reported that a subanesthetic dose of ketamine elicits rapid and sustained antidepressant effects in patients with depression. Subsequent clinical studies replicated these effects in treatment-resistant major depression (8,9) and treatment-resistant bipolar depression (10,11). Furthermore, recent meta-analyses demonstrated that ketamine exhibits rapid and sustained antidepressant effects in treatment-resistant patients with depression (12-15). Interestingly, ketamine has been reported to demonstrate a rapid reduction of suicidal ideation in treatment-resistant patients with depression (16-19). In contrast, it is well known that ketamine produces acute transient psychotomimetic side effects after single or repeated infusions (7, 8, 10, 11, 20, 21) . However, no data are available regarding the efficacy and safety of ketamine maintenance (longer-term) therapy delivered intravenously, intranasally, or via other routes (22). In addition, the addictive potential of ketamine also warrants concern because ketamine abuse is a widely recognized social problem in many countries, including the United States as well as countries in Asia and Europe (22). Therefore, it is likely that the psychotomimetic side effects and abuse potential of ketamine should not be ignored (23) (24) (25) (26) (27) (28) (29) .
Ketamine is a racemic mixture comprising equal parts of (R)-ketamine (arketamine) and (S)-ketamine (esketamine). (S)-Ketamine exhibits an approximately three-to fourfold greater binding affinity for N-methyl-D-aspartate receptor than (R)-ketamine, which pharmacologically explains the fact that (S)-ketamine has an approximately fourfold greater anesthetic potency and greater undesirable psychotomimetic side effects than (R)-ketamine (4-6,30). (R)-Ketamine has more potent and longer-lasting antidepressant effects than (S)-ketamine in the animal models of depression (31-34). Furthermore, a single bilateral infusion of (R)-ketamine into the infralimbic cortex of the medial prefrontal cortex (PFC) and the cornu ammonis 3 (CA3) and dentate gyrus (DG) of the hippocampus demonstrates antidepressant effects (35), suggesting that these brain regions play a role in the direct antidepressant actions of (R)-ketamine. Unlike (S)-ketamine, (R)-ketamine appears to be ª 2017 Society of Biological Psychiatry. 
